Acquisition Opportunity: Preclinical Contract Research Organization with Highly Experienced Research Team and Strategic Laboratory Assets

We are pleased to bring to your attention a rare opportunity to acquire a premier, 60-year-old Contract Research Organization (CRO) specializing in high-barrier pre-clinical trial services. This organization operates as a trusted service partner to global pharmaceutical, biotechnology, and medical device sponsors, offering comprehensive GLP-compliant toxicology and safety evaluations in the drug discovery space. Key Investment Highlights: • Long-Established Reputation: The firm has a six-decade history of scientific research excellence, currently serving long-standing relationships with the NIH, CDC, NAID, NCI, Department of Defense (DOD), and others. • Premier Specialized Facilities: The firm owns and operates a 100,000 sq. ft. laboratory located on a major university campus. These state-of-the-art facilities include BSL-2 and BSL-3+ containment suites, microbiology / molecular biology and bioanalytical chemistry resources, high-tech inhalation exposure suites, and a full-service animal vivarium. The laboratories are equipped with the latest technology equipment. There is negligible debt on all these assets (the real estate is debt-free). • Operational Stability: The CRO has a stable history of revenues and cash flow. Many drug sponsors are repeat customers. Most independent market research firms forecast a minimum 8% CAGR for CROs (like this firm) engaged in pre-clinical trial services through 2034, paralleling growth in the drug discovery market. • Specialized Expertise: Market-leading capabilities in inhalation toxicology, infectious disease research, and Investigational New Drug (IND) and New Drug (NDA) applications. The technical team boasts an exceptional average tenure of well over 10 years, providing deep institutional knowledge. • Strategic Conversion Opportunity: Currently operating as a 501(c)(3) nonprofit, there is an opportunity to initiate a formal conversion to for-profit status concurrent with the sale. This conversion could unlock operational efficiencies, significant tax advantages (asset step on PP&E, allocation of purchase price to goodwill, etc.), and M&A opportunities for a strategic or financial acquirer. Tom Korzenecki, redacted